Compare SMJF & MOLN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
| Metric | SMJF | MOLN |
|---|---|---|
| Founded | 1988 | 2004 |
| Country | Singapore | Switzerland |
| Employees | N/A | N/A |
| Industry | | |
| Sector | | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 123.8M | 144.0M |
| IPO Year | N/A | 2021 |
| Metric | SMJF | MOLN |
|---|---|---|
| Price | $3.17 | $4.41 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $8.38 |
| AVG Volume (30 Days) | ★ 582.6K | 1.9K |
| Earning Date | 05-08-2026 | 05-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $374.07 |
| P/E Ratio | $68.08 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.82 | $3.36 |
| 52 Week High | $5.70 | $5.36 |
| Indicator | SMJF | MOLN |
|---|---|---|
| Relative Strength Index (RSI) | 43.93 | 49.35 |
| Support Level | $2.19 | $4.04 |
| Resistance Level | $3.74 | $4.50 |
| Average True Range (ATR) | 0.21 | 0.16 |
| MACD | 0.01 | 0.03 |
| Stochastic Oscillator | 6.15 | 66.78 |
SMJ International Holdings Inc specializes in the sale and distribution of a wide range of flooring products such as carpet tiles, broadloom carpets and vinyl tiles. The company operates under the proprietary brand 'SMJ'.The company also supplies environmentally friendly flooring products, promoting sustainable building practices in Asia. It has presence in several countries including Malaysia, Indonesia, Philippines, Hong Kong, PRC, Taiwan, Korea, Thailand, Vietnam, Brunei, and India. It generates revenue mainly through the sale and distribution of its flooring products prominently in Singapore.
Molecular Partners AG is a clinical stage biopharmaceutical company. The Company has programs in various stages of pre-clinical and clinical development, with oncology as its main focus. The firm develops protein therapeutics called DARPin therapeutics for the treatment of serious diseases, including cancer and sight-threatening disorders. The company is currently focusing on oncology through their robust pipeline of clinical and preclinical programs, with particular attention to MP0712, the key Radio-DARPin candidate targeting DLL3 now in a Phase 1/2a trial in the United States.